FDA Approves YONSA — Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries received FDA approval for its generic oral formulation of abiraterone acetate (NDA 210308) on May 22, 2018. The entry of a branded generic positions the company to contend in a lucrative oncology market currently dominated by approved brand-name competitors.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day